Journey Medical (DERM) Expected to Release Earnings on Wednesday

Journey Medical (NASDAQ:DERM) is anticipated to announce its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Journey Medical to post earnings of ($0.03) per share and revenue of $20.32 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.

Journey Medical (NASDAQ:DERM) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.02) by $0.01. The firm had revenue of $18.51 million during the quarter, compared to the consensus estimate of $18.36 million. Journey Medical had a negative return on equity of 20.23% and a negative net margin of 8.95%. On average, analysts expect Journey Medical to post ($0.13) EPS for the current fiscal year and $0.44 EPS for the next fiscal year.

Journey Medical Price Performance

NASDAQ DERM opened at $4.64 on Wednesday. Journey Medical has a 12 month low of $4.31 and a 12 month high of $9.56. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.59 and a quick ratio of 1.41. The business has a fifty day simple moving average of $6.39 and a 200 day simple moving average of $6.64.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on DERM shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a research report on Thursday, October 15th. Wall Street Zen downgraded Journey Medical from a “buy” rating to a “hold” rating in a research note on Saturday, October 17th. B. Riley Financial reiterated a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of Journey Medical in a research note on Thursday, August 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Journey Medical in a research report on Monday, October 26th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $14.00.

Journey Medical Company Profile

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and commercializing prescription products for medical dermatology. The company targets conditions that affect the skin, hair and nails, with an emphasis on products that address significant patient needs and can be marketed through its specialty sales organization.

Its portfolio includes Qbrexza (glycopyrronium) cloth, a topical treatment for primary axillary hyperhidrosis, and Targadox (doxycycline hyclate) delayed-release capsules, which are used to treat moderate-to-severe inflammatory acne vulgaris.